- Companies
- BioSerenity
BioSerenity Funding, Investors & Competitors
BioSerenity has raised $121M across 5 funding rounds, most recently a $26M undisclosed-stage round in November 2023.
Last BioSerenity funding round
$26M
Undisclosed stage · Nov 2023
Cumulative funding BioSerenity raised
$121M
across 5 funding rounds
Key investors in BioSerenity
Idinvest Partners
Bpifrance
LBO France
Kurma Partners
WILCO
Innovation Capital
Dassault Systemes
Jolt Capital
About BioSerenity
BioSerenity is a Paris-based neurotech firm specializing in epilepsy diagnostics. Its Neuronaute wearable records 24/7 EEG with video and motion tracking, anonymizing data for researchers at Institut du Cerveau et Moelle Épinière. Launched in 2014, the system analyzes 10,000 seizures from 2,000 patients, aiding AI model training. BioSerenity expands to sleep disorders, serving 50 French hospitals and exporting to the US.
Founded
2014
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
BioSerenity Funding History
BioSerenity has raised a total of $121M across 5 funding rounds.
BioSerenity's first fundraising round was a $200K pre-seed round in September 2014. The most recent completed round was a $26M undisclosed-stage round in November 2023.
BioSerenity funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Nov 2023 | Undisclosed stage | Jolt Capital (lead) | $26M | BioSerenity, founded in 2014, specializes in connected medical devices and software for electroencephalography (EEG), extending to sleep disorders and neurological diagnostics. The company offers products like Neuronaute and Icecap hardware, CE-marked and FDA-cleared, along with AI-based diagnostic software (LR), protected by over 30 international patents. It serves more than 300 partners, treats 150,000 patients annually, and has reached over 1 million patients total by July 2023. On November 13, 2023, Jolt Capital, a private equity firm focused on European deeptech growth investments, announced a €24 million (approximately $25.65M-$26.1M USD) investment in BioSerenity. This private equity round brings the company's total funding to $119.87M across 9 rounds. Jolt Capital is the sole investor listed for this round, aligning with its strategy in advanced healthcare data technologies. The funding supports acceleration of international expansion, building on key markets in France and the United States while targeting Europe, deployment of advanced AI for improved diagnostics in telemedicine, and strengthening of the management team, including the appointment of Vincent Marcel as CEO. BioSerenity positions itself as a leader in neurology and sleep disorder solutions with market-proven technologies. The investment underscores investor confidence in BioSerenity's proprietary tech amid healthcare innovation needs, with Jolt Capital highlighting its fit for significant financing to drive development. |
| Jun 2019 | Series B | Dassault Systemes (lead); LBO France; Idinvest Partners; Bpifrance | $74M | BioSerenity, a French medtech company specializing in connected medical devices and remote-monitoring solutions for patients with cardiac, neurological, and sleep disorders, raised approximately $56-73 million in a Series B funding round on June 18-19, 2019. The round was led by Dassault Systèmes, with participation from Bpifrance, Idinvest Partners (also referred to as IDInvest Partners), and LBO France. Dassault Systèmes took a non-controlling interest in BioSerenity as part of this investment, aligning with their 2019 strategy to expand in life sciences and healthcare through targeted acquisitions and stakes in innovative firms. This move complemented other major activities that year, such as the acquisition of Medidata Solutions, positioning life sciences as their second-largest revenue source. The funding occurred amid a robust month for medical devices venture financing, totaling $661.16M globally, with BioSerenity's deal contributing significantly to the top five totaling $294.34M. |
| Sep 2017 | Series A | LBO France (lead); Idinvest Partners; Bpifrance; Innovation Capital | $18M | BioSerenity develops a platform connecting patients with healthcare providers via smart and connected clothes in the digital health sector based in France. LBO France led the investment in BioSerenity in 2017, with the company listed as in portfolio and classified under private equity. The round amount was approximately $17.8 million. BioSerenity has raised a total of $119.87 million over 9 rounds, with investors including LBO France, Bpifrance, IDInvest Partners, JOLT Capital, and SCOR Life & Health Ventures. |
| Nov 2015 | Seed | Kurma Partners (lead); Idinvest Partners | $3M | BioSerenity is a French startup specializing in wearable medical device solutions for epilepsy diagnosis and medical diagnostics, launched in January 2014 and located within the Brain and Spine Institute of Paris. The company raised 3 million Euros in a seed round from Kurma Diagnostics and Idinvest Partners. Kurma Partners led the investment, marking the first investment from their newly launched diagnostics fund. |
| Sep 2014 | Pre-seed | WILCO | $200K | - |
Who has invested in BioSerenity?
8 investors have backed BioSerenity across its funding rounds, including Idinvest Partners, Bpifrance, LBO France, Kurma Partners, WILCO and Innovation Capital.
Lead investors include Jolt Capital, Dassault Systemes, LBO France and Kurma Partners.
BioSerenity Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Nov 2015 | ||
| 2 | Lead | Sep 2017 | ||
| 2 | Participant | Sep 2017 | ||
| 1 | Lead | Nov 2023 | ||
| 1 | Lead | Nov 2015 | ||
| 1 | Participant | Sep 2014 | ||
This data is available for Pro users. Sign up to see all 8 BioSerenity investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialInvestments by BioSerenity
BioSerenity has invested in 1 company to date.
Latest investment by BioSerenity was on April 5th 2024. BioSerenity invested in BOYDSense in their $8M Series A round.
Latest Investments by BioSerenity
| Description | BOYDSense is a South San Francisco-headquartered biotechnology company developing non-invasive breath analysis devices for chronic disease diagnostics. The firm captures volatile organic compounds in exhaled breath to detect biomarker patterns for conditions like asthma, diabetes, and metabolic disorders. Founded in 2015, BOYDSense employs metabolomics platforms combining sensors, AI algorithms, and cloud-based analytics for real-time monitoring. Its tools target clinical settings, consumer wellness, and telemedicine, partnering with healthcare providers to enable affordable at-home testing. |
| HQ Country | |
| HQ City | San Francisco, CA |
| Deal Date | 5 Apr 2024 |
| Round | Series A |
| Raised | $8M |
| Investors | European Innovation Council; Ambrosia Investments; Jolt Capital; Swiss Diabetes Venture Fund; Sweet Ventures; Alpha MOS |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all BioSerenity investments and their VC round multiples. Start Free Trial | |
BioSerenity Competitors
BioSerenity competitors include listed companies like IQVIA, ICON plc and Privia Health, and private ones like Innovaccer, NantHealth and Unite Us.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Private | $250M | - | $3.5B | 13.8x | ||
| Publicly listed | $2.1B | $44M | $2.6B | 0.9x | ||
| Private | $58M | - | $2B | - | ||
| Private | - | - | $1.6B | - |
BioSerenity Public Comps
BioSerenity is still privately-owned, but its public comps include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Revvity, Solventum, Tempus AI, ICON plc and Pro Medicus.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
| $2.9B | $735M | 6.5x | 6.6x | 25.4x | 21.0x | |||
| $8.3B | $2.5B | 2.4x | 2.4x | 7.8x | 8.9x | |||
| $1.3B | ($131M) | 12.0x | 10.1x | (116.0x) | 346.0x | |||
This data is available for Pro users. Sign up to see all BioSerenity competitors and their valuation data. Start Free Trial | ||||||||
Common questions about BioSerenity
| When was BioSerenity founded? | BioSerenity was founded in 2014. |
| Where is BioSerenity headquartered? | BioSerenity is headquartered in Paris, France. |
| Is BioSerenity publicly listed? | No, BioSerenity is a private, VC-backed company. |
| How much funding has BioSerenity raised? | BioSerenity has raised $121M across 5 funding rounds. |
| What was BioSerenity's last funding round? | BioSerenity's last funding round was a $26M undisclosed-stage round in November 2023, led by Jolt Capital. |
| Who are BioSerenity's investors? | BioSerenity's investors include Idinvest Partners, LBO France, Bpifrance, Jolt Capital, Kurma Partners, WILCO, Innovation Capital and Dassault Systemes. |
| Which companies are comparable to BioSerenity? | Companies comparable to BioSerenity include IQVIA, ICON plc, Innovaccer, Privia Health, NantHealth and Unite Us. |
| How many companies has BioSerenity invested in? | BioSerenity has invested in 1 company, including BOYDSense. |
| What was BioSerenity's last investment? | In April 2024, BioSerenity invested in BOYDSense's $8M Series A alongside European Innovation Council, Ambrosia Investments, Jolt Capital and 3 other investors. |
See companies similar to BioSerenity
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




